<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00187057</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1</org_study_id>
    <nct_id>NCT00187057</nct_id>
  </id_info>
  <brief_title>Study for Treatment of Cancer in Children With Ataxia-telangiectasia</brief_title>
  <official_title>Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot/feasibility study designed to investigate the feasibility of treating&#xD;
      children with Ataxia-Telangiectasia (A-T) and cancer with regimens nearly as intense as&#xD;
      non-A-T patients with cancer would receive.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 10-30% of A-T patients will develop a malignancy during their lifetime. The&#xD;
      vast majority of these cancers are of lymphoid origin. There is no consensus regarding the&#xD;
      optimal strategy for treating children with A-T who develop hematopoietic malignancies.&#xD;
      Historically, many of these children have been treated with therapy that is much less&#xD;
      intensive than the conventional approach for non-A-T patients with similar malignancies&#xD;
      during the corresponding treatment era. Although these less intensive approaches may have&#xD;
      stemmed from perceptions that these children would not tolerate intensive therapy, there is&#xD;
      in fact no data to suggest that these children cannot tolerate intensive therapy. However, it&#xD;
      is clear that children with A-T require a modification in certain components of intensive&#xD;
      therapy.&#xD;
&#xD;
      To provide children with A-T and either ALL or malignant lymphoma the best chance for a cure,&#xD;
      we propose to use modern therapeutic strategies with minimal modifications which address the&#xD;
      unique toxicity profile encountered in treating children with A-T.&#xD;
&#xD;
      Secondary objectives include:&#xD;
&#xD;
        -  To clinically and biologically characterize the malignancies occurring in children with&#xD;
           A-T (usually malignant lymphoma or ALL). This will include in vitro drug sensitivity&#xD;
           screening.&#xD;
&#xD;
        -  To study chemotherapy-induced DNA damage in children with A-T.&#xD;
&#xD;
      Detailed Description of Treatment Plan:&#xD;
&#xD;
        -  Acute Lymphoblastic Leukemia (ALL) Low Risk:&#xD;
&#xD;
      Induction:&#xD;
&#xD;
      Prednisone 40 mg/m2/day PO days 1-28&#xD;
&#xD;
      Vinblastine 6 mg/m2/dose IV day 8&#xD;
&#xD;
      Vincristine 1.5 mg/m2/dose days 1, 15&#xD;
&#xD;
      Daunomycin 20 mg/m2/week IV days 1,15&#xD;
&#xD;
      Asparaginase 10,000 U/m2/dose IM days 2, 4, 6, 8, 10, 12&#xD;
&#xD;
      VP-16 225 mg/m2/dose Days 22, 25, 29&#xD;
&#xD;
      Ara-C 300 mg/m2/dose Days 22, 25, 29&#xD;
&#xD;
      All patients will receive CNS therapy with triple intrathecal therapy on days 1, 22 and 43 of&#xD;
      induction treatment, dose age adjusted.&#xD;
&#xD;
      Consolidation:&#xD;
&#xD;
      Methotrexate 2 mg/m2 IV day 43 and 50 and mercaptopurine 75 mg/m2 days 43-56.&#xD;
&#xD;
      Continuation therapy (120 weeks):&#xD;
&#xD;
      Week:&#xD;
&#xD;
        1. 6-MP + MTX&#xD;
&#xD;
        2. 6-MP + MTX&#xD;
&#xD;
        3. 6-MP + MTX&#xD;
&#xD;
        4. Dex + VCR&#xD;
&#xD;
        5. 6-MP + MTX&#xD;
&#xD;
        6. 6-MP + MTX&#xD;
&#xD;
        7. 6-MP + HDMTX&#xD;
&#xD;
        8. Dex + VCR&#xD;
&#xD;
        9. 6-MP + MTX&#xD;
&#xD;
       10. 6-MP + MTX&#xD;
&#xD;
       11. 6-MP + MTX&#xD;
&#xD;
       12. Dex + VCR&#xD;
&#xD;
       13. 6-MP + MTX&#xD;
&#xD;
       14. 6-MP + MTX&#xD;
&#xD;
       15. 6-MP + HDMTX&#xD;
&#xD;
      This sequence will be repeated through week 52 after which 6-MP + MTX will be given weekly to&#xD;
      complete 120 weeks. IT MHA (MTX, hydrocortisone, Ara-C) on weeks 1, 2, 7, and 15 and then&#xD;
      every 4-8 weeks depending on CNS status.&#xD;
&#xD;
      Dosages, Schedules and Routes:&#xD;
&#xD;
      6-MP 75 mg/m2 PO; daily x 7&#xD;
&#xD;
      MTX 40 mg/m2 IM or IV; q (every) week;&#xD;
&#xD;
      Dex 6 mg/m2 PO; in 3 divided doses daily x 7&#xD;
&#xD;
      VCR 1.5 mg/m2 IV (max. 2.0 mg)&#xD;
&#xD;
      HDMTX 2 g/m2 IV over 2 hours, every 8 weeks&#xD;
&#xD;
      Reinduction:&#xD;
&#xD;
      Reinduction therapy (weeks 16-21). Reinduction therapy (same as initial induction treatment&#xD;
      minus dose 2 and 3 of VP16 +ara-C and minus day 22 intrathecal therapy) will be given after&#xD;
      bone marrow examination on week 15 confirms complete remission.&#xD;
&#xD;
        -  Acute Lymphoblastic Leukemia (ALL) - High Risk&#xD;
&#xD;
      Induction:&#xD;
&#xD;
      Prednisone 40 mg/m2/day PO) divided in 3 doses days 1-28&#xD;
&#xD;
      Vinblastine 6 mg/m2/dose IV day 8&#xD;
&#xD;
      Vincristine 1.5 mg/m2/dose days 1, 15&#xD;
&#xD;
      Daunomycin 20 mg/m2/week IV days 1, 15&#xD;
&#xD;
      Asparaginase 10,000 U/m2/dose IM days 2, 4, 6, 8, 10, 12, (15, 17, 19)&#xD;
&#xD;
      VP16 225 mg/m2/dose days 22, 25, 29&#xD;
&#xD;
      Ara-C 300 mg/m2/dose days 22,25,29&#xD;
&#xD;
      All patients will receive triple IT therapy on days 1, 22 and 43 of induction with additional&#xD;
      IT therapy on days 8 and 15 if CNS leukemia (CNS 2 or CNS 3) is present at diagnosis. If&#xD;
      required, for patients with CNS 2 and 3 at diagnosis, IT therapy will continue until 2&#xD;
      consecutive CSF studies are normal (i.e., days 29 and 36).&#xD;
&#xD;
      Consolidation:&#xD;
&#xD;
      HDMTX 2 mg/m2 IV day 43 and 50&#xD;
&#xD;
      6 MP 75 mg/m2 PO days 43-56&#xD;
&#xD;
      Continuation Therapy (120 weeks):&#xD;
&#xD;
      Week:&#xD;
&#xD;
        1. Dex + VCR&#xD;
&#xD;
        2. VP-16 + CTX&#xD;
&#xD;
        3. 6-MP + MTX&#xD;
&#xD;
        4. MTX + Ara-C&#xD;
&#xD;
        5. Dex + VCR&#xD;
&#xD;
        6. VP-16 + CTX&#xD;
&#xD;
        7. 6-MP + HDMTX&#xD;
&#xD;
        8. 6-MP + MTX&#xD;
&#xD;
        9. Dex + VCR&#xD;
&#xD;
       10. VP-16 + CTX&#xD;
&#xD;
       11. 6-MP + MTX&#xD;
&#xD;
       12. MTX + Ara-C&#xD;
&#xD;
       13. Dex + VCR&#xD;
&#xD;
       14. VP-16 + CTX&#xD;
&#xD;
       15. 6-MP + HDMTX&#xD;
&#xD;
      These sequences will be repeated through week 52, after which 6MP/MTX will be given weekly to&#xD;
      complete 120 weeks.&#xD;
&#xD;
      IT MHA (MTX, hydrocortisone, Ara-C) on weeks 1, 2, 7, and 15 and then every 4-8 weeks&#xD;
      depending on CNS status and risk status.&#xD;
&#xD;
      Dosages, Schedules and Routes:&#xD;
&#xD;
      VP 16 225 mg/m2 IV once a week&#xD;
&#xD;
      Cyclophosphamide 300 mg/m2 IV (with MESNA) once a week in addition to the 6 hour IV hydration&#xD;
&#xD;
      6-MP 75 mg/m2 PO; daily x 7&#xD;
&#xD;
      MTX 40 mg/m2 IM or IV once a week&#xD;
&#xD;
      Ara-C 300 mg/m2 IV push; once a week&#xD;
&#xD;
      Dex 8 mg/m2/day PO; in 3 divided doses daily x 7&#xD;
&#xD;
      VCR 1.5 mg/m2 IV push (max. 2.0 mg)&#xD;
&#xD;
      HDMTX 2 g/m2 IV over 2 hours; every 8 weeks x 7&#xD;
&#xD;
        -  B-Cell Non-Hodgkins Lymphoma&#xD;
&#xD;
      Overview - the chemotherapy regimen used varies with grouping based on extent of disease&#xD;
&#xD;
      Group A&#xD;
&#xD;
      Induction (COPAD x 2 cycles):&#xD;
&#xD;
      Cyclophosphamide 500 mg/m2/day (divided every 12 hour) IV (with MESNA) Day 1, 2, 3&#xD;
&#xD;
      Vincristine 2.0 mg/m2 IV Day 1&#xD;
&#xD;
      Vinblastine 6 mg/m2 IV Day 6&#xD;
&#xD;
      Prednisone 60 mg/m2/day (bid) PO Day 1-5&#xD;
&#xD;
      Adriamycin 50 mg/m2 (over 6 hrs) IV Day 1&#xD;
&#xD;
      G-CSF 5 mcg/kg/day until count recovery.&#xD;
&#xD;
      Group B&#xD;
&#xD;
      COP Induction:&#xD;
&#xD;
      Cyclophosphamide 300 mg/m2 IV (divided every 12 hours) IV (with MESNA) Day 1&#xD;
&#xD;
      Vincristine 1.0 mg/m2 IV Day 1&#xD;
&#xD;
      Prednisone 60 mg/m2/day (divided bid) PO days 1-7&#xD;
&#xD;
      CNS Therapy Intrathecal Day 1 - dose age adjusted&#xD;
&#xD;
      COPAD-M3 Induction x 2 cycles:&#xD;
&#xD;
      Vinblastine 6 mg/m2 IV Day 1&#xD;
&#xD;
      HD MTX 3 mg/m2 IV over 3 hours Day 1 with leucovorin rescue&#xD;
&#xD;
      CNS Therapy intrathecal each age adjusted Day 2, 6&#xD;
&#xD;
      Cyclophosphamide 500 mg/m2/day (second course 1 mg/m2/day) IV (with MESNA) Day 2, 3, 4&#xD;
&#xD;
      Adriamycin 50 mg/m2 IV Day 2&#xD;
&#xD;
      Prednisone 60 mg/m2 (divided bid) PO Day 1-5&#xD;
&#xD;
      G-CSF 5 mcg/kg/day until count recovery&#xD;
&#xD;
      CYM Consolidation x 2 cycles:&#xD;
&#xD;
      HD MTX 3 mg/m2 IV over 3 hours Day 1 with leucovorin rescue&#xD;
&#xD;
      Ara-C 100 mg/m2/day CI/IV (x 5 days) Day 2-6&#xD;
&#xD;
      CNS Therapy intrathecal each age adjusted Day 2 and 7&#xD;
&#xD;
      Maintenance:&#xD;
&#xD;
      Prednisone 60 mg/m2/day (divided bid) PO Day 1-5&#xD;
&#xD;
      HDMTX 3 mg/m2 IV over 3 hours Day 1 with leucovorin rescue&#xD;
&#xD;
      CNS Therapy intrathecal each age adjusted Day 2&#xD;
&#xD;
      Cyclophosphamide 500 mg/m2/day IV (with MESNA) Day 2, 3&#xD;
&#xD;
      Adriamycin 50 mg/m2 IV Day 3&#xD;
&#xD;
      Vincristine 2 mg/m2 IV Day 1&#xD;
&#xD;
      G-CSF 5 mcg/kg/day until count recovery&#xD;
&#xD;
        -  Limited Stage Non-Hodgkins Lymphoma&#xD;
&#xD;
      Induction:&#xD;
&#xD;
      Vincristine 2 mg/m2 IV days 1, 22 (maximum dose 2 mg)&#xD;
&#xD;
      Vinblastine 6 mg/m2 IV, day 8&#xD;
&#xD;
      Prednisone 40 mg/m2/day in 3 divided doses x 28 days&#xD;
&#xD;
      Adriamycin 30 mg/m2/day IV over one hour days 1 and 22&#xD;
&#xD;
      Cyclophosphamide 750 mg/m2/day IV days 1 and 22&#xD;
&#xD;
      Triple IT chemotherapy for participants with head and neck primary tumors on days 1, 8, 22.&#xD;
      Each dose age adjusted.&#xD;
&#xD;
      Consolidation - start day 43:&#xD;
&#xD;
      Adriamycin 30 mg/m2 by IV&#xD;
&#xD;
      Cyclophosphamide 750 mg/m2&#xD;
&#xD;
      Prednisone 40 mg/m2 in 3 divided doses x 5 days&#xD;
&#xD;
      Vincristine 2.0 mg/m2 (max. 2.0 mg) by IV&#xD;
&#xD;
      Triple IT chemotherapy for head and neck primaries on days 43 and 64.&#xD;
&#xD;
      Maintenance:&#xD;
&#xD;
      Maintenance chemotherapy will be administered only to patients with lymphoblastic lymphoma&#xD;
      and will consist of 24 weeks of chemotherapy with oral daily 6-MP and weekly oral&#xD;
      methotrexate (and TIT every 6 weeks for patients with head and neck primaries) after&#xD;
      induction/consolidation.&#xD;
&#xD;
        -  Hodgkins Disease&#xD;
&#xD;
      Participants with favorable disease will receive VAMP chemotherapy:&#xD;
&#xD;
      VAMP chemotherapy doses and schedule:&#xD;
&#xD;
      Vinblastine 6 mg/m2, IV day 1, 15 (maximum dosage: 10 mg)&#xD;
&#xD;
      Adriamycin 25 mg/m2, IV day 1, 15&#xD;
&#xD;
      Methotrexate 20 mg/m2, IV day 1, 15&#xD;
&#xD;
      Prednisone 40 mg/m2 PO day 1-14 divided into 3 daily doses&#xD;
&#xD;
      Repeat cycle every 28 days, total number of cycles = 6 (NO RADIATION THERAPY)&#xD;
&#xD;
      Participants with unfavorable disease will receive VAMP and COP:&#xD;
&#xD;
      VAMP chemotherapy doses (cycles 1, 3, 5, 7)&#xD;
&#xD;
      Vinblastine 6 mg/m2 IV day 1, 15&#xD;
&#xD;
      Adriamycin 25 mg/m2 IV day 1,15&#xD;
&#xD;
      Methotrexate 20 mg/m2 IV day 1, 15&#xD;
&#xD;
      Prednisone 40 mg/m2 (divided into 3 daily doses) PO day 1-14&#xD;
&#xD;
      COP chemotherapy doses (cycles 2, 4, 6, 8)&#xD;
&#xD;
      Cyclophosphamide 600 mg/m2 IV (with MESNA) day 1, 8&#xD;
&#xD;
      Vincristine 1.4 mg/m2 IV day 1,8 (max dose 2 mg)&#xD;
&#xD;
      Procarbazine 100 mg/m2 PO day 1-14&#xD;
&#xD;
      (NO RADIATION THERAPY)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the feasibility of delivering modified intensive chemotherapy to children with A-T who present with cancer.</measure>
    <time_frame>The completion of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Ataxia-Telangiectasia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acute Lymphoblastic Leukemia (ALL) Low Risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acute Lymphoblastic Leukemia (ALL) - High Risk</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>B-Cell Non-Hodgkins Lymphoma (Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>B-Cell Non-Hodgkins Lymphoma (Group B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hodgkins Disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine, vincristine, prednisone, daunorubicin</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin, methotrexate, cyclophosphamide, L-asparaginase</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide, cytarabine, mercaptopurine</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone, procarbazine</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemotherapy, intrathecal chemotherapy, steroid therapy</intervention_name>
    <description>See Detailed Description section for details of treatment interventions.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3A</arm_group_label>
    <arm_group_label>3B</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have a diagnosis of Ataxia-Telangiectasia (A-T).&#xD;
&#xD;
          -  Patient must have a diagnosis of either acute lymphoblastic leukemia (ALL) or lymphoma&#xD;
             (non-Hodgkin lymphoma or Hodgkin's disease).&#xD;
&#xD;
          -  Patients with other malignancies (solid tumors, rare malignancies, or relapsed&#xD;
             hematopoietic malignancies) will be eligible for the biologic studies of this&#xD;
             protocol; they will receive best clinical management chemotherapy.&#xD;
&#xD;
          -  Patients do not have to be previously untreated. If prior chemotherapy has already&#xD;
             started (up through induction), therapy will be continued according to protocol at a&#xD;
             clinically appropriate time point.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not have a diagnosis of Ataxia Telangiectasia (A-T).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John T. Sandlund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <reference>
    <citation>Sandlund JT, Kastan MB, Kennedy W, Behm F, Entrekin E, Pui CH, Kalwinsky DT, Raimondi SC. A subtle t(3;8) results in plausible juxtaposition of MYC and BCL6 in a child with Burkitt lymphoma/leukemia and ataxia-telangiectasia. Cancer Genet Cytogenet. 2006 Jul 1;168(1):69-72.</citation>
    <PMID>16772123</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ataxia</keyword>
  <keyword>alphafetoprotein</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Ataxia Telangiectasia</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

